downtown-skyline-philadelphia-pennsylvania-twilight
All Events

ISPOR 2026

  • Start Date:

    17 May 2026

  • End Date:

    20 May 2026

  • Location:

    Philadelphia, US

  • Booth #:

    611

Schedule a meeting

Proof Over Promise: AI, Data & Decision-Grade Evidence at ISPOR 2026

ISPOR’s Top 10 HEOR Trends 2026–2027 ranks AI as the #1 trend—but in market access, value is defined by decision impact, not speed.

We bring scientific rigor, commercial insight, and technical excellence to help you apply AI responsibly across the product lifecycle. Grounded in fit-for-purpose data and expert human oversight, our portfolio spans RWD strategy, economic modeling, real-world outcomes research, patient preference and utility studies, and market access guidance. From data curation and cohort identification to outcome prediction and evidence synthesis, we deliver transparent, decision-grade evidence built to meet the expectations of HTA bodies, payers, and regulators.

Partner with us to move from potential to proof—because AI doesn’t replace HEOR judgment – it amplifies it. 

Schedule a meeting
ISPOR 2026 corporate partner

Visit conference website

Educational symposium

Monday, 18 May • 12:15pm – 1:15pm
Transforming HEOR with Artificial Intelligence and Real-World Data

Speakers: Mark Yates, Ashwin Kumar Rai, Melissa Ross, Apoorva Ambavane

Forums

Tuesday, 19 May • 12:15pm – 1:15pm
Aligning HEOR With Global Policy Shifts: How Should We Lead and Influence?

Speaker: Priya Jain

Tuesday, 19 May • 4:45pm – 5:45pm
Following the Trail: A Journey of Individual Patient Preference Data from Response to Analysis to Clinical Encounter

Speaker: Jennifer Whitty

Workshop

Monday, 18 May • 1:45pm – 2:45pm
Use of Agentic AI to Create Health Economic Models in Both R and Excel

Speakers: J. Jaime Caro (Moderator), Apoorva Ambavane

Breakout session

Tuesday, 19 May • 1:45pm – 2:45pm
Beyond Cronbach’s Alpha: Modern Reliability Assessment for COA Research and Regulatory Decision-Making

Speakers: Danielle Rodriguez, Patrick Daniele

Short course

Sunday, 17 May • 1:00pm – 5:00pm
PROs in Clinical Trials: Endpoint Selection, Regulatory Strategy and Label Claims

Speaker: Heather Gelhorn

Poster presentations

  ISPOR Top 5% Poster

Monday, May 18

Session 1

Indirect treatment comparisons in relapsed or refractory multiple myeloma: Insights from recent NICE submissions

Shujun Li, Juan Idarraga, Denise Zou

From GPT-4 to GPT-5.2: A comparative evaluation of large language models for extracting clinical real-world evidence data (RWE)

Mariana Farraia, Anuja Pandey, Kassandra Schaible, Caroline von Wilamowitz-Moellendorff

Automated study feasibility: Leveraging agentic AI to rapidly identify right fit secondary data

N Sawalhi-Leckenby, M Yates, Graham S, Lambrelli D, Raluy Callado M, Rai A

Use of item response theory to create multi-dimensional measures of financial toxicity in cancer

Salene Jones, Matt Barnett, Jean Yi, Nora Henrikson, Diana Lowry, Renae Lydum, Laura Panattoni

Changes in pain and stiffness experienced by patients with tenosynovial giant cell tumor (TGCT) in the maneuver phase 3 trial: Insights from exit interviews

Vinod Ravi, Paul Kamudoni, Andrea Phillips Beyer, Niki Karachaliou, Amy Clark, Agkreta Leventi, Savita Bakhshi Anand, Carla Dias Barbosa, Hans Gelderblom

Monday, May 18

Session 2

Using shortfall metrics to prioritize therapeutic innovation in oncology

Ariel Sun, Neda Aminnejad, Sonja Sorensen

Context-aware generative AI for evidence generation, analog-driven enrollment forecasting, and operational risk management in oncology trials

Ashwin Rai, Victorio Ikoro Devika Bhandary, Andre Ng, Marielle Bassel

New failure modes, old standards: why artificial intelligence (AI) demands different validation approaches in evidence synthesis

Priccila Zuchinali, Kassandra Schaible, Allie Cichewicz

A portfolio modeling framework for HEOR decision making

Sonja Sorensen, Ariel Sun, Neda Aminnejad

Increasing efficiency of systematic literature reviews: Are multiple databases necessary?

Kassandra Schaible, Monica Turner

Identifying (dis-)agreement between models for evaluation of effectiveness of risk minimization measures (RMMS)

MA Natividad Sancho

Insights into range of motion (ROM) and physical function (PF) changes experienced by patients with tenosynovial giant cell tumor (TGCT) in the maneuver phase 3 trial: Results from exit interviews

Vinod Ravi, Paul Kamudoni, Andrea Phillips Beyer, Niki Karachaliou, Qingping Zou, Amy Clark, Agkreta Leventi, Savita Bakhshi Anand, Carla Dias Barbosa, Hans Gelderblom

Tuesday, May 19

Session 3

Pre-approval information exchange (PIE) in the United States. Trends following the passage of the PIE act: Where are we now?

Anna De Boer, Don Smith

What HTA bodies criticize in indirect treatment comparisons for advanced cancers: A thematic analysis of recent HTA reports in solid tumors

Marissa Betts, Nicholas Parr, Jo Campbell, Kyle Fahrbach

Surviving unanchored indirect comparisons: an extension of multilevel unanchored meta-regression (ML-UMR) for survival analyses

Conor Chandler, Jack Ishak

Understanding perspectives, barriers and enablers for clinical trial participation in representative patient populations

K Meginnis, H Clarke, E Webb, A Skalicky, O Babalola, T Gray, D Gebben, L Perreras, M Malone, R Wright, C Grossman, J Whitty

A structured framework for sampling strategy design in large-scale real-world chart review studies

Lauren Gianchetti, Neil Brett, Marielle Bassel

Tuesday, May 19

Session 4

Performance of adaptive smart tags in nested knowledge for automated extraction of study characteristics

Priccila Zuchinali, Sophie Yoon, Joanna Kamar, Amber Martin

A qualitative study to explore patient perspectives on future gene therapy for limb girdle muscular dystrophy (LGMD) sarcoglycanopathy subtypes 2E/R4, 2D/R3, and 2C/R5

I Audhya, A Nacson, H Collacott, N Ramachandran, MK Ladd, K Gooch, J Whitty

Neurologist preferences for new MS treatments: Implications for market access prioritization in the United States and Europe

Sarah Mulnick, Jennifer A. Whitty, Gabriela S. Fernandez, Sebastian Heidenreich, Janneke Van Wingerden, Nupur Greene

Wednesday, May 20

Session 5

Economic analyses of gender-affirming care: A literature review

K. Sandman, M. Andrawes

Can PubMed alone capture the evidence base for targeted literature reviews? A case study

Priscilla WittKopf, Rajat Goel, Kassandra Schaible, Caroline von Wilamowitz-Moellendorff

Using AI to map HEOR evidence gaps: Findings from a large-scale LLM-based classification analysis

Weicheng Ye, Corrina Mau, Denise Zou

Partner with us to move from potential to proof

because AI doesn’t replace HEOR judgment – it amplifies it.

Schedule a meeting